Latest Breaking News On - Valerie sullivan - Page 4 : comparemela.com
etectRx Announces Launch of MyTPill Study to Address Medication Adherence Among HIV+ Prescription Opioid Users
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BB lv: А сухие фрукты – лучше!
bb.lv - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bb.lv Daily Mail and Mail on Sunday newspapers.
Are Digital Pills in Your Future?
New pills raise privacy and ethical concerns over their ability to send a signal to up to 5 people when taken
In November 2017, the FDA approved the digital pill Abilify MyCite to treat schizophrenia, depression, and bipolar disorder(1); a one-month supply costs $1,500, well out of range of affordability for many suffering from schizophrenia(2).
The pill includes a digital sensor that reacts with stomach acid when taken, sending a signal to a patch worn by the patient that then sends a signal to a smartphone app notifying up to five people that the pill was taken.
Share
Earlier this week DTx company Pear Therapeutics inked a deal with adherence tool etectRx to potentially develop a product that combines the former’s digital therapeutics with a digital pill offering. As part of the deal the two companies will meet quarterly to discuss potential collaborations with the pharma industry.
“Here we are talking about how can we bring this to pharma. we are going to quarterly, and we are going to talk about the market: Hey, what is pharma doing out there in clinical trials? Combing clinicaltrials.gov and approach them, and say could a combined solution like ours advance our clinical trials?” Valerie Sullivan, CEO of etectRx told
etectRx Announces Agreement to Advance Digital Sensors for Medication Adherence in Combination with Prescription Digital Therapeutics
News provided by
Share this article
Share this article
GAINESVILLE, Fla., Jan. 14, 2021 /PRNewswire/ Digital health company, etectRx, Inc., announced today that it has entered into an agreement with Pear Therapeutics, Inc. to develop up to two product candidates in the Central Nervous System (CNS) space combining Prescription Digital Therapeutics (PDTs) and adherence sensors. The collaboration is the first of its kind to explore the use of digital pill solutions with PDTs. This collaboration between etectRx and Pear Therapeutics comes at a critical time for the mental health field, an area that is in dire need of immediate solutions, said Valerie Sullivan, president and CEO of etectRx. Our goal for this collaboration is to bring concrete solutions to those who need it.
vimarsana © 2020. All Rights Reserved.